Loading...

David Oh, MD, PhD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue
San Francisco CA 94117
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard CollegeAB2000Biochemical Sciences
    Stanford University School of MedicineMD/PhD2011Medicine, Physiology
    University of California, San FranciscoResidency2014Internal Medicine
    University of California, San FranciscoFellowship2017Hematology/Oncology
    Collapse Awards and Honors
    University of California, San Francisco2015Clinical Fellow Award
    Conquer Cancer Foundation of American Society of Clinical Oncology 2016Merit Award
    University of California, San Francisco2016Molecular Pathology of Cancer T32
    Conquer Cancer Foundation of American Society of Clinical Oncology2017Young Investigator Award
    Bladder Cancer Advocacy Network2018Young Investigator Award
    Prostate Cancer Foundation2018Young Investigator Award

    Collapse Overview 
    Collapse Overview
    I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.

    Clinically, I see patients in the Cancer Immunotherapy Program where I am an attending physician, principal investigator, and co-investigator on early-phase/first-in-human trials testing novel immunotherapies in advanced solid tumors, with a particular focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, intratumoral immunotherapy, and adoptive cell therapies.

    In the laboratory, I study samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment.

    Collapse Research 
    Collapse Research Activities and Funding
    Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
    NIH/NIAID K08AI139375Mar 1, 2019 - Feb 29, 2024
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 Aug 19. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 32813112.
      View in: PubMed   Mentions:    Fields:    
    2. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 25; 181(7):1612-1625.e13. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. PMID: 32497499.
      View in: PubMed   Mentions:    Fields:    
    3. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. J Immunother Cancer. 2020 05; 8(1). Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. PMID: 32376721.
      View in: PubMed   Mentions:    Fields:    
    4. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Front Immunol. 2019; 10:2985. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. PMID: 31993050.
      View in: PubMed   Mentions: 1     Fields:    
    5. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Dig Dis Sci. 2019 03; 64(3):685-688. Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG. PMID: 30778872.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. PMID: 30737146.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    7. Immunity in the Time of Metastases. Immunity. 2018 12 18; 49(6):1002-1003. Oh DY, Fong L. PMID: 30566878.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology. 2019; 8(1):e1486953. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. PMID: 30546940.
      View in: PubMed   Mentions:
    9. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res. 2017; 77(6):1322-1330. Oh DY, * Cham J, * Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author.
    10. Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):3029-3029. David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong. .
      View in: Publisher Site   Mentions:
    11. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8. Oh DY, Venook AP, Fong L. PMID: 26285242.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    12. Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes. Immunity. 2009; 31(6):986-98. Ehrlich LI, * Oh DY, * Weissman IL, Lewis RS. *co-first author.
    13. Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nat Immunol. 2005 Feb; 6(2):143-51. Bhakta NR, Oh DY, Lewis RS. PMID: 15654342.
      View in: PubMed   Mentions: 89     Fields:    Translation:AnimalsCells
    14. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003 Mar 07; 112(5):659-72. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. PMID: 12628186.
      View in: PubMed   Mentions: 167     Fields:    Translation:HumansCells
    15. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001 Nov 16; 276(46):43285-93. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J. PMID: 11555662.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    16. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol. 2000; 165(12):6915-21. Gommerman JL, * Oh DY, * Zhou X, Tedder TF, Maurer M, Galli SJ, Carroll MC. *co-first author.
    David's Networks
    Concepts (102)
    Derived automatically from this person's publications.
    _
    Co-Authors (25)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _